In Fight to End Nation's Opioid Crisis, a New Treatment Approach Emerges

Seven years after the industry-leading Hazelden Betty Ford Foundation overhauled its approach to treating opioid addiction, research shows its new model is producing successful outcomes.

The naturalistic, prospective study followed 253 adult patients with opioid use disorder who were admitted to Hazelden Betty Ford's residential treatment facility in Center City, Minnesota, between June 2013 and June 2017. Patients participating in COR-12™ received opioid-specific therapy, education and case management; were given the option of Suboxone, Vivitrol or no medication; and participated in the rest of Hazelden Betty Ford's treatment model, which utilizes the best evidence-based clinical practices and systematically connects patients to peer support and other recovery resources.

Learn more the peer-reviewed study and research outcomes.